Talaroconvolutine A

Talaroconvolutin A is a ferroptosis inducer. Talaroconvolutin A induces ferroptosis by increasing reactive oxygen species (ROS) levels rather than the GPX4 pathway. Talaroconvolutin A downregulates the expression of the channel protein solute carrier family 7 member 11 (SLC7A11) and upregulates arachidonic acid lipoxygenase 3 (ALOXE3) . Talaroconvolutin A inhibits the growth of colorectal cancer cells HCT116 and bladder cancer cells SW480 with IC50 values of 1.22 μM and 1.4 μM, respectively. Talaroconvolutin A can be used in the study of colorectal cancer and bladder cancer[1][2][3].

273199-42-1

12352005

Ferroptosis; p38 MAPK; Reactive Oxygen Species (ROS)

Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB

Cancer-Kinase/protease

Cancer

O=C(C1=C/C(NC1=O)=C/C2=CC=C(C=C2)O)[C@H]3[C@@]4([H])[C@](C=C([C@H]3/C(C)=C/[C@@H](C)CC)C)(C[C@@H](CC4)C)C

C32H41NO3

487.67

[1]Xia Y, et al. Discovery of a novel ferroptosis inducer-talaroconvolutin A-killing colorectal cancer cells in vitro and in vivo. Cell Death Dis. 2020 Nov 17;11 (11) :988.|[2]Xia Y, et al. Proteomics, Transcriptomics, and Phosphoproteomics Reveal the Mechanism of Talaroconvolutin-A Suppressing Bladder Cancer via Blocking Cell Cycle and Triggering Ferroptosis. Mol Cell Proteomics. 2023 Dec;22 (12) :100672.|[3]Wang P, et al. Two New Succinimide Derivatives Cladosporitins A and B from the Mangrove-derived Fungus Cladosporium sp. HNWSW-1. Mar Drugs. 2018 Dec 20;17 (1) :4.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-N15742/

Natural Products

No Development Reported